Navigation Links
Organovo Reports Q3 2012 Financial Results, Provides Business Update
Date:11/16/2012

SAN DIEGO, Nov. 16, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three and nine month period ended September 30, 2012.

Third Quarter Corporate Highlights

  • National Institutes of Health three dimensional liver research grant revenue
  • Receipt of two issued patents, including Company's first assigned patent
  • Move to new, larger research and headquarters facility
  • Appointment of additional independent director to serve as Audit Committee Chairman
  • Third quarter 2012 revenues increased by $237,300 or approximately 102% over the same period in 2011, commensurate with the Company's continued delivery against collaborative research agreements and the initiation of research activities within the scope of a grant from the National Institutes of Health ("NIH").  Collaborative research agreement revenues contributed $141,800 or 60% of the revenue increase while grant revenues contributed $95,500.

    Cash receipts related to the reported revenues partially offset the Company's operating expenses and strengthened our balance sheet.  During the quarter the balance sheet was additionally strengthened through the receipt of approximately $1.7 million in capital from warrant and stock option exercises.  The Company had approximately $7.7 million cash on hand at the end of the quarter.  While the Company reported net earnings of approximately $38.5 million for the quarter, investors should note those earnings were primarily the result of a non-cash adjustment resulting from the change in fair value of our warrant liabilities.  The warrant liability is volatile in nature and is driven primarily by changes in the price of our Common stock, absent material changes in the number of warrants outstanding.  Investors should anticipat
    '/>"/>

    SOURCE Organovo Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
    2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
    3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
    4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
    5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
    6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
    7. Organovo To Present At Lazard Healthcare Conference
    8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    10. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    11. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
    (Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
    (Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
    (Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
    Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
    ... will form the basis of a DNA diagnostic test to identify women ... into ... deCODEme(TM), REYKJAVIK, Iceland, April 27 ... of two common,single-letter variants (SNPs) on chromosome 5 of the human genome ...
    ... SAN DIEGO, April 25 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Global,Healthcare Unplugged Conference in Key Biscayne, FL on Thursday, ... PT. Daniel M. Bradbury, President and,Chief Executive Officer of ... live presentation and breakout session will be webcast, and ...
    ... LINTHICUM, Md., April 25 Dialysis Corporation,of America (Nasdaq: ... its first,quarter 2008 financial results on May 7, 2008, ... host a conference call in conjunction with,its first quarter ... 10:00 AM EDT., Those interested in participating in ...
    Cached Biology Technology:deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 5Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2
    (Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
    (Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
    (Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
    Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
    ... Nanyang Technological University (NTU) and Imperial College London today ... medical school. The initiative was previously announced by Prime ... 2010, in August. Presently, the working name for the ... (ICNMS). To start in 2013, ICNMS will ...
    ... & Science University Doernbecher Children,s Hospital will lead the ... assess the safety and preliminary effectiveness of purified human ... infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare ... children. The Phase Ib trial, sponsored by StemCells, ...
    ... parenting skills. Most species leave their freshly hatched fry ... Buckley from the University of Plymouth, UK, explains that ... parents secrete over their bodies until they are big ... is very unusual, says Buckley. Intrigued by the fish,s ...
    Cached Biology News:Imperial and NTU's new medical school aspires to be global health care role model 2Imperial and NTU's new medical school aspires to be global health care role model 3Imperial and NTU's new medical school aspires to be global health care role model 4OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study 2Discus fish parent young like mammalian mothers 2
    ... DNase I Amplification ... double-stranded DNA to oligodeoxyribonucleotides. ... >10000 units/mg. DNAse I ... purified and tested for ...
    ... for the determination of digitonin and digoxin. Physical ... Na 4 and 0.06% NaCl Preparation Note: ... Biochem. Biophys. Res. Commun., 19, 755 (1965). ... of inorganic phosphorus from ATP per min at ...
    ... ds Qualified is a special preparation of bovine ... double stranded cleavage of DNA molecules. In the ... enzyme makes double strand breaks at random sites ... fragments can be controlled by the enzyme concentration ...
    ... type 14 3C protease from human rhinovirus ... the Novagen brand line of restriction grade ... purified recombinant 6XHis-fusion protein, which recognizes the ... LeuGluValLeuPheGln/GlyPro. The small, 22 KDa size of ...
    Biology Products: